Strategic Funding Signal Boston Scientific led a $175M Series D for 4C in March 2025, signaling strong strategic validation and potential for co-selling or distribution partnerships. Leverage this relationship to access major hospital networks and large health systems.

Differentiated MR Frame 4C’s transcatheter mitral therapy preserves the native annulus and LV with supra-annular atrial-only fixation, offering a differentiated value proposition to structural heart programs. Target top-tier centers with mature MR programs for early adoption and data generation.

TR Expansion Opportunity The roadmap to address tricuspid regurgitation after MR provides cross-sell potential within the same institutions and patient populations, enabling broader market reach and higher procedural volumes per program.

Funding Supports Scale Current revenue is in the tens of millions with substantial Series D funding, enabling scale-out of field teams, clinical evidence development, and market expansion in the US and potential international markets.

Competitive Positioning In a landscape with large incumbents, 4C can accelerate adoption through differentiated technology and potential OEM or joint development partnerships, supported by investor backing and strategic alignments.